var data={"title":"Reteplase (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Reteplase (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6905?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=reteplase-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Reteplase (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217795\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Retavase Half-Kit [DSC];</li>\n      <li>Retavase [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217796\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Retavase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217828\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Thrombolytic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217799\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note: Retavase and Retavase Half-Kit have been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>STEMI:</b> IV: 10 units IV over 2 minutes, followed by a second dose 30 minutes later of 10 units IV over 2 minutes; withhold second dose if serious bleeding or anaphylaxis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Thrombolytic should be administered within 30 minutes of hospital arrival.</b> Generally, there is only a small trend for benefit of therapy after a delay of 12 to 24 hours from symptom onset, but thrombolysis may be considered for selected patients with ongoing ischemic pain and extensive ST elevation; however, primary PCI is preferred in these patients. Administer concurrent aspirin, clopidogrel, and anticoagulant therapy (ie, unfractionated heparin, enoxaparin, or fondaparinux) with reteplase (O&rsquo;Gara, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990374\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment provided in manufacturer&rsquo;s labeling. However, risks of reteplase therapy may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable: Unknown, but unlikely (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987757\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling. However, risks of reteplase therapy may be increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217800\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217780\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Retavase: 10.4 units [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Retavase Half-Kit: 10.4 units [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217765\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28803832\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Retavase and Retavase Half-Kit have been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217782\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Reconstituted dose should be administered IV over 2 minutes; no other medication should be added to the injection solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217781\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of ST-elevation myocardial infarction (STEMI) for the improvement of ventricular function, the reduction of the incidence of CHF, and the reduction of mortality following STEMI</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommended criteria for treatment of STEMI (ACCF/AHA; O&rsquo;Gara, 2013): Ischemic symptoms within 12 hours of treatment or evidence of ongoing ischemia 12-24 hours after symptom onset with a large area of myocardium at risk or hemodynamic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">STEMI ECG definition: New ST-segment elevation at the J point in at least 2 contiguous leads of &ge;2 mm (0.2 mV) in men or &ge;1.5 mm (0.15 mV) in women in leads V<sub>2</sub>-V<sub>3</sub> and/or of &ge;1 mm (0.1 mV) in other contiguous precordial leads or limb leads on ECG. New or presumably new left bundle branch block (LBBB) may interfere with ST-elevation analysis and should not be considered diagnostic in isolation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">At non-PCI-capable hospitals, the ACCF/AHA recommends thrombolytic therapy administration when the anticipated first medical contact (FMC)-to-device time at a PCI-capable hospital is &gt;120 minutes due to unavoidable delays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2973287\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217772\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Bleeding is the most frequent adverse effect associated with reteplase. Heparin and aspirin have been administered concurrently with reteplase in clinical trials. The incidence of adverse events is a reflection of these combined therapies, and is comparable to comparison thrombolytics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Bleeding at injection site (5% to 49%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (2% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (genitourinary: 1% to 10%), anemia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, atheromatous embolism, hypersensitivity reaction, intracranial hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217785\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Active internal bleeding; history of cerebrovascular accident; recent (ie, within 2 months) intracranial or intraspinal surgery or trauma; intracranial neoplasm, arteriovenous malformations, or aneurysm; known bleeding diathesis; severe uncontrolled hypertension</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Additional contraindications (ACCF/AHA [O&rsquo;Gara, 2013]): Ischemic stroke within 3 months; prior intracranial hemorrhage; active bleeding (excluding menses); suspected aortic dissection; significant closed head or facial trauma within 3 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217769\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis: Rare anaphylactic reactions can occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: Monitor all potential bleeding sites. If serious bleeding occurs, the infusion of reteplase and heparin should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions that increase bleeding risk: For the following conditions the risk of bleeding is higher with use of reteplase and should be weighed against the benefits of therapy: recent (within 10 days) major surgery (eg, CABG, obstetrical delivery, organ biopsy), recent puncture of noncompressible vessels, cerebrovascular disease, recent gastrointestinal or genitourinary bleeding, recent trauma including CPR, hypertension (systolic BP &gt;180 mm Hg and/or diastolic BP &gt;110 mm Hg), high likelihood of left heart thrombus (eg, mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, hemostatic defects including ones caused by severe renal or hepatic dysfunction, significant hepatic or renal dysfunction, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, septic thrombophlebitis or occluded AV cannula at seriously infected site, or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of location. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myocardial infarct (MI): Appropriate use: Follow standard management for MI while infusing reteplase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. Adjunctive use of parenteral anticoagulants (eg, enoxaparin, heparin, or fondaparinux) is recommended to improve vessel patency and prevent reocclusion (ACCF/AHA; O&rsquo;Gara, 2013); however, these may also contribute to bleeding; monitor for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in patients with advanced age (eg, &gt;75 years); increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Intramuscular injections and nonessential handling of the patient should be avoided. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299994\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217774\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9857&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217776\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13447525\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. The risk of bleeding may be increased in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548294\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if reteplase is excreted in breast milk. The manufacturer recommends that caution be exercised when administering reteplase to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217778\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs of bleeding (hematuria, GI bleeding, gingival bleeding); CBC, PTT; ECG monitoring</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217768\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reteplase is a nonglycosylated form of tPA produced by recombinant DNA technology using <i>E. coli</i>; it initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217784\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Thrombolysis: 30-90 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 13-16 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces and urine </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Plasma: 250-450 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323783\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Retavase Half-Kit Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10.4 unit (1): $2605.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Retavase Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10.4 unit (1): $5211.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217787\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pai Tong Xin (CN);</li>\n      <li>Rapilysin (AE, AT, AU, BE, BG, BH, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IS, IT, LT, LU, MT, NL, NZ, PL, PT, QA, RO, RU, SE, SG, SI, SK, TR);</li>\n      <li>Rui Tong Li (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;A Comparison of Reteplase With Alteplase for Acute Myocardial Infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators,&rdquo; <i>N Engl J Med</i>, 1997, 337(16):1118-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/9340503/pubmed\" target=\"_blank\" id=\"9340503\">9340503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Luca G, Suryapranata H, Stone GW, et al, &ldquo;Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials,&rdquo; <i>JAMA</i>, 2005, 293(14):1759-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/15827315/pubmed\" target=\"_blank\" id=\"15827315\">15827315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ellis SG, Tendera M, de Belder MA, et al, &ldquo;Facilitated PCI in Patients With ST-Elevation Myocardial Infarction,&rdquo; <i>N Engl J Med</i>, 2008, 358(21):2205-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/18499565/pubmed\" target=\"_blank\" id=\"18499565\">18499565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keeley EC, Boura JA, and Grines CL, &quot;Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-Elevation Myocardial Infarction: Quantitative Review of Randomised Trials,&quot; <i>Lancet</i>, 2006, 367(9510):579-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/16488801/pubmed\" target=\"_blank\" id=\"16488801\">16488801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al, &ldquo;2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 51(2):172-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/18191745/pubmed\" target=\"_blank\" id=\"18191745\">18191745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Califf RM, Van de Werf F, et al, &ldquo;Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial,&rdquo; <i>JAMA</i>, 2002, 288(17):2130-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/12413372/pubmed\" target=\"_blank\" id=\"12413372\">12413372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor RE, Brady W, Brooks SC, et al, &ldquo;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/20956226/pubmed\" target=\"_blank\" id=\"20956226\">20956226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smalling RW, Bode C, Kalbfleisch J, et al, &ldquo;More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction. RAPID Investigators,&rdquo; <i>Circulation</i>, 1995, 91(11):2725-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/7758177/pubmed\" target=\"_blank\" id=\"7758177\">7758177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol EJ, GUSTO V Investigators, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,&rdquo; <i>Lancet</i>, 2001, 357:1905-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/reteplase-united-states-not-available-drug-information/abstract-text/11425410/pubmed\" target=\"_blank\" id=\"11425410\">11425410</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9857 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F217795\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F217796\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F217828\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F217799\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990374\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987757\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F217800\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F217780\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F217765\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28803832\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F217782\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F217781\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2973287\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F217772\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F217785\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F217769\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299994\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F217774\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F217776\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13447525\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20548294\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F217778\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F217768\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F217784\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323783\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F217787\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9857|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=reteplase-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Reteplase (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}